Immunotherapy of triple negative breast cancer
05/2019
Doc. MUDr. Josef Dvořák, PhD.1, MUDr. Igor Richter, Ph.D.2, MUDr. Jan Prokš1, MUDr. Aneta Rozsypalová1, MUDr. Jana Grimová3
1 Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
2 Oddělení klinické onkologie, Krajská nemocnice Liberec, a.s.
3 Onkocentrum Medicon, a.s., Praha
SUMMARY
Triple negative breast cancer constitutes a heterogeneous group of diseases with limited systemic treatment options. A new perspective treatment modality is immunotherapy with check point inhibitors. The phase III randomized control trial IMpassion130 demonstrated a significantly prolonged progression free survival and overall survival in first line treatment of metastatic or locally advanced inoperable triple negative breast cancer with atezolizumab and nab-paclitaxel, exclusively in patients with programmed death-ligand 1 (PD-L1) ≥ 1 % expression on tumor infiltrating immune cells.
Key words
triple negative breast cancer, immunotherapy, check point inhibitors, atezolizumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...